IL249628A0 - Nucleosides, modified nucleotides and their analogs - Google Patents
Nucleosides, modified nucleotides and their analogsInfo
- Publication number
- IL249628A0 IL249628A0 IL249628A IL24962816A IL249628A0 IL 249628 A0 IL249628 A0 IL 249628A0 IL 249628 A IL249628 A IL 249628A IL 24962816 A IL24962816 A IL 24962816A IL 249628 A0 IL249628 A0 IL 249628A0
- Authority
- IL
- Israel
- Prior art keywords
- nucleotides
- analogs
- substituted nucleosides
- nucleosides
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462016232P | 2014-06-24 | 2014-06-24 | |
| US201462061770P | 2014-10-09 | 2014-10-09 | |
| PCT/US2015/037001 WO2015200219A1 (en) | 2014-06-24 | 2015-06-22 | Substituted nucleosides, nucleotides and analogs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL249628A0 true IL249628A0 (en) | 2017-02-28 |
Family
ID=54868668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL249628A IL249628A0 (en) | 2014-06-24 | 2016-12-18 | Nucleosides, modified nucleotides and their analogs |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9603864B2 (OSRAM) |
| EP (2) | EP3160476B1 (OSRAM) |
| JP (3) | JP6728075B2 (OSRAM) |
| CN (2) | CN106573011A (OSRAM) |
| AU (2) | AU2015280248B2 (OSRAM) |
| CA (2) | CA3207106A1 (OSRAM) |
| DK (1) | DK3160476T3 (OSRAM) |
| EA (1) | EA201692535A1 (OSRAM) |
| ES (1) | ES2841310T3 (OSRAM) |
| HR (1) | HRP20202014T1 (OSRAM) |
| HU (1) | HUE051986T2 (OSRAM) |
| IL (1) | IL249628A0 (OSRAM) |
| LT (1) | LT3160476T (OSRAM) |
| MX (1) | MX2016017383A (OSRAM) |
| PH (1) | PH12016502564A1 (OSRAM) |
| SG (1) | SG11201610599TA (OSRAM) |
| SI (1) | SI3160476T1 (OSRAM) |
| SM (1) | SMT202000716T1 (OSRAM) |
| TW (1) | TW201613612A (OSRAM) |
| WO (1) | WO2015200219A1 (OSRAM) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2794627T3 (pl) | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Podstawione nukleozydy, nukleotydy i ich analogi |
| US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EA201590943A1 (ru) | 2012-12-21 | 2016-01-29 | Алиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
| HK1216535A1 (zh) | 2012-12-21 | 2016-11-18 | Alios Biopharma, Inc. | 取代的核苷、核苷酸及其類似物 |
| US9504705B2 (en) | 2013-04-05 | 2016-11-29 | Alios Biopharma, Inc. | Hepatitis C viral infection treatment using a combination of compounds |
| AU2014302715B2 (en) | 2013-06-26 | 2018-12-06 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| ES2952714T3 (es) | 2013-06-26 | 2023-11-03 | Janssen Pharmaceuticals Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos |
| SG10201804835VA (en) * | 2013-10-11 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| SG11201610599TA (en) | 2014-06-24 | 2017-01-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015200205A1 (en) | 2014-06-24 | 2015-12-30 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EA031726B1 (ru) | 2014-09-26 | 2019-02-28 | Рибосайенс Ллк | 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса |
| CN107108681B (zh) | 2014-10-28 | 2021-04-06 | 詹森生物制药有限公司 | 制备取代的核苷类似物的方法 |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| CN107427529A (zh) | 2014-12-26 | 2017-12-01 | 埃莫里大学 | N4‑羟基胞苷和衍生物及与其相关的抗病毒用途 |
| KR102363946B1 (ko) | 2015-03-06 | 2022-02-17 | 아테아 파마슈티컬즈, 인크. | HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드 |
| CA2979216A1 (en) | 2015-03-11 | 2016-09-15 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| CN105503787A (zh) * | 2015-12-31 | 2016-04-20 | 阜阳欣奕华材料科技有限公司 | 一种索非布韦中间体的纯化方法 |
| PT3433257T (pt) | 2016-03-24 | 2023-11-29 | Novartis Ag | Análogos nucleosídeos de alquinil como inibidores do rinovírus humano |
| EA201892448A1 (ru) * | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| HRP20220278T1 (hr) | 2016-09-07 | 2022-05-13 | Atea Pharmaceuticals, Inc. | 2'-supstituirani-n6-supstituirani purinski nukleotidi za liječenje bolesti izazvanih rnk virusima |
| JP7125144B2 (ja) | 2016-09-09 | 2022-08-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| US11643432B2 (en) | 2016-12-16 | 2023-05-09 | National University Corporation Tokai National Higher Education And Research System | Nucleoside derivative and use thereof |
| IL295609B2 (en) | 2017-02-01 | 2023-11-01 | Atea Pharmaceuticals Inc | Nucleotide hemisulfate salt for the treatment of hepatitis C virus |
| JP2020518578A (ja) | 2017-05-01 | 2020-06-25 | ギリアード サイエンシーズ， インコーポレイテッド | （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態 |
| CA3077489A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| CA3071612A1 (en) | 2017-07-31 | 2019-02-07 | January Therapeutics, Inc. | Organophosphate derivatives |
| CR20200126A (es) | 2017-09-18 | 2020-07-11 | Janssen Biopharma Inc | Nucleósidos sustituidos, nucleótidos y análogos de estos |
| WO2019088179A1 (ja) | 2017-10-31 | 2019-05-09 | ヤマサ醤油株式会社 | ヌクレオシド誘導体及びその利用 |
| ES2995458T3 (en) | 2017-12-07 | 2025-02-10 | Univ Emory | N4-hydroxycytidine derivative and anti-viral uses related thereto |
| AU2019227986A1 (en) * | 2018-03-02 | 2020-10-08 | January Therapeutics, Inc. | Nanoparticle compositions |
| CN119633010A (zh) * | 2018-03-07 | 2025-03-18 | 埃默里大学 | 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途 |
| WO2019200005A1 (en) | 2018-04-10 | 2019-10-17 | Atea Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
| MA55200A (fr) | 2019-03-06 | 2022-01-12 | Glaxosmithkline Ip No 2 Ltd | Composés utiles dans la thérapie du vih |
| KR20240113860A (ko) * | 2019-04-05 | 2024-07-23 | 가부시기가이샤 닛뽕쇼꾸바이 | 가교형 인공 뉴클레오시드의 제조 |
| WO2021137913A2 (en) * | 2019-10-08 | 2021-07-08 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CN118766947A (zh) | 2020-01-27 | 2024-10-15 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| EP4644394A2 (en) | 2020-02-18 | 2025-11-05 | Gilead Sciences, Inc. | Antiviral compounds |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN113387954B (zh) * | 2020-03-11 | 2024-03-19 | 上海特化医药科技有限公司 | 一种瑞德西韦中间体的制备方法 |
| TWI890963B (zh) | 2020-03-12 | 2025-07-21 | 美商基利科學股份有限公司 | 1'-氰基核苷之製備方法 |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CN115335387A (zh) * | 2020-03-27 | 2022-11-11 | 住友化学株式会社 | 核酸寡聚物的制造方法 |
| EP4125912B1 (en) * | 2020-03-27 | 2025-07-30 | R.G.C.C. Holdings AG | Compounds for the in vitro inhibition of the rna-dependent rna polymerase of coronaviruses |
| CN115362004A (zh) | 2020-04-06 | 2022-11-18 | 吉利德科学公司 | 1’-氰基取代的碳核苷类似物的吸入制剂 |
| UY39172A (es) * | 2020-04-14 | 2021-10-29 | Janssen Sciences Ireland Unlimited Co | Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e |
| ES3041698T3 (en) | 2020-05-29 | 2025-11-13 | Gilead Sciences Inc | Remdesivir for the treatment of viral infections |
| JP2023531524A (ja) | 2020-06-24 | 2023-07-24 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノヌクレオシド類似体及びその使用 |
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| IL300453A (en) | 2020-08-27 | 2023-04-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| CN112279877B (zh) * | 2020-12-15 | 2021-08-06 | 南京颐媛生物医学研究院有限公司 | 一种核苷磷酸酯及其合成方法 |
| CN113214320A (zh) * | 2021-01-23 | 2021-08-06 | 河南泰丰生物科技有限公司 | 一种瑞德西韦化合物的制备方法 |
| WO2022174194A1 (en) * | 2021-02-15 | 2022-08-18 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| BR112023020600A2 (pt) * | 2021-04-09 | 2023-12-12 | Univ Emory | Método para tratar ou prevenir uma infecção, e, uso de um composto |
| KR20230170745A (ko) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| MX2023014898A (es) | 2021-06-17 | 2024-04-29 | Atea Pharmaceuticals Inc | Terapia combinada anti-vhc ventajosa. |
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| CN113735929A (zh) * | 2021-07-21 | 2021-12-03 | 海化生命(厦门)科技有限公司 | 一种抗冠状病毒的化合物及其制备方法与应用 |
| WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| CN115721661A (zh) * | 2021-09-01 | 2023-03-03 | 常晓宇 | 嘌呤核苷类药物预防或治疗冠状病毒感染性疾病的用途 |
| CN113461760B (zh) * | 2021-09-06 | 2021-12-10 | 南京颐媛生物医学研究院有限公司 | 4-硫代脱氧胸苷衍生物及其抗乙肝病毒制药应用 |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| WO2023069495A1 (en) * | 2021-10-19 | 2023-04-27 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides |
| US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
| CN116554249B (zh) * | 2022-01-28 | 2025-03-18 | 北京恩泰伟医药科技有限公司 | 抗病毒化合物及其用途 |
| TW202525810A (zh) | 2022-03-02 | 2025-07-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| JP2025509635A (ja) | 2022-03-15 | 2025-04-11 | ローム・セラピューティクス・インコーポレイテッド | 疾患を治療するための化合物及び方法 |
| US20250282812A1 (en) * | 2022-04-20 | 2025-09-11 | Shanghai Institute Of Materia Medica , Chinese Academy Of Sciences | Antiviral nucleoside analogue, and pharmaceutical composition and use thereof |
| JPWO2024034644A1 (OSRAM) * | 2022-08-10 | 2024-02-15 | ||
| WO2024086592A2 (en) * | 2022-10-17 | 2024-04-25 | Emory Unversity | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CN116589510B (zh) * | 2023-04-20 | 2025-08-26 | 安徽大学 | 一种氟代苄基核糖中间体的制备方法与应用 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| PT2251015E (pt) | 2000-10-18 | 2013-04-15 | Gilead Pharmasset Llc | Nucleosídeos modificados para o tratamento de infeções virais e de proliferação celular anormal |
| BR0206614A (pt) | 2001-01-22 | 2004-02-17 | Merck & Co Inc | Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto |
| JP2005533817A (ja) * | 2002-06-28 | 2005-11-10 | イデニクス（ケイマン）リミテツド | フラビウィルス科ウィルス感染治療用の修飾２′および３′−ヌクレオシドプロドラッグ |
| US20040259934A1 (en) * | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
| WO2005020884A2 (en) * | 2003-05-14 | 2005-03-10 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
| WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| JP2008508319A (ja) * | 2004-07-29 | 2008-03-21 | メタバシス・セラピューティクス・インコーポレイテッド | 新規ヌクレオシド誘導体 |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8633308B2 (en) * | 2007-02-28 | 2014-01-21 | The Governors Of The University Of Alberta | Compounds for preventing or treating viral infections and methods of use thereof |
| WO2010015643A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| EP2408306A4 (en) | 2009-03-20 | 2012-11-07 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES |
| US20100240604A1 (en) * | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Protected nucleotide analogs |
| EP2619215B1 (en) | 2010-09-22 | 2018-09-05 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| CA2810928A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| WO2012040126A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| CN102558261A (zh) * | 2010-12-17 | 2012-07-11 | 中国科学院大连化学物理研究所 | 一种核苷酸类似物及其合成和应用 |
| WO2012088155A1 (en) | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| CN103687866A (zh) * | 2011-05-19 | 2014-03-26 | Rfs制药公司 | 用于治疗病毒性感染的嘌呤单磷酸酯前药 |
| SG11201403364PA (en) | 2011-12-20 | 2014-07-30 | Hoffmann La Roche | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
| US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| PL2794627T3 (pl) | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Podstawione nukleozydy, nukleotydy i ich analogi |
| WO2013142159A1 (en) | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| UA113980C2 (uk) | 2012-03-21 | 2017-04-10 | Аліос Біофарма, Інк. | Заміщені нуклеозиди, нуклеотиди і їх аналоги |
| NZ630800A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Methods of preparing substituted nucleotide analogs |
| NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
| US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| FR3000193B1 (fr) | 2012-12-20 | 2015-01-16 | Msc & Sgcc | Procede et dispositif de mesure de la verticalite sur un recipient |
| EA201590943A1 (ru) | 2012-12-21 | 2016-01-29 | Алиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
| HK1216535A1 (zh) | 2012-12-21 | 2016-11-18 | Alios Biopharma, Inc. | 取代的核苷、核苷酸及其類似物 |
| TW201526899A (zh) | 2013-02-28 | 2015-07-16 | Alios Biopharma Inc | 醫藥組成物 |
| US20140309413A1 (en) | 2013-03-11 | 2014-10-16 | Vertex Pharmaceuticals Incorporated | Methods of stereoselective synthesis of substituted nucleoside analogs |
| US9504705B2 (en) | 2013-04-05 | 2016-11-29 | Alios Biopharma, Inc. | Hepatitis C viral infection treatment using a combination of compounds |
| AU2014250764A1 (en) | 2013-04-12 | 2015-10-29 | Achillion Pharmaceuticals, Inc. | Deuterated nucleoside prodrugs useful for treating HCV |
| ES2952714T3 (es) | 2013-06-26 | 2023-11-03 | Janssen Pharmaceuticals Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos |
| AU2014302715B2 (en) | 2013-06-26 | 2018-12-06 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP3043803B1 (en) | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
| SG10201804835VA (en) | 2013-10-11 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015200205A1 (en) | 2014-06-24 | 2015-12-30 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| SG11201610599TA (en) | 2014-06-24 | 2017-01-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| AU2015280245A1 (en) | 2014-06-24 | 2017-01-05 | Alios Biopharma, Inc. | Methods of preparing substituted nucleotide analogs |
| WO2016014398A1 (en) | 2014-07-22 | 2016-01-28 | Alios Biopharma, Inc. | Methods for treating paramyxoviruses |
| CA2957017A1 (en) | 2014-08-05 | 2016-02-11 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
| CN107108681B (zh) | 2014-10-28 | 2021-04-06 | 詹森生物制药有限公司 | 制备取代的核苷类似物的方法 |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| TW201811339A (zh) | 2016-08-12 | 2018-04-01 | 美商艾洛斯生物製藥公司 | 經取代之核苷、核苷酸及其類似物 |
| WO2018081449A1 (en) | 2016-10-27 | 2018-05-03 | Alios Biopharma, Inc. | Methods for treating respiratory syncytial virus infection |
-
2015
- 2015-06-22 SG SG11201610599TA patent/SG11201610599TA/en unknown
- 2015-06-22 EA EA201692535A patent/EA201692535A1/ru unknown
- 2015-06-22 SI SI201531469T patent/SI3160476T1/sl unknown
- 2015-06-22 HR HRP20202014TT patent/HRP20202014T1/hr unknown
- 2015-06-22 LT LTEP15812231.7T patent/LT3160476T/lt unknown
- 2015-06-22 ES ES15812231T patent/ES2841310T3/es active Active
- 2015-06-22 DK DK15812231.7T patent/DK3160476T3/da active
- 2015-06-22 CN CN201580045439.9A patent/CN106573011A/zh active Pending
- 2015-06-22 HU HUE15812231A patent/HUE051986T2/hu unknown
- 2015-06-22 SM SM20200716T patent/SMT202000716T1/it unknown
- 2015-06-22 EP EP15812231.7A patent/EP3160476B1/en active Active
- 2015-06-22 JP JP2016575488A patent/JP6728075B2/ja active Active
- 2015-06-22 EP EP20192890.0A patent/EP3797782A1/en not_active Ceased
- 2015-06-22 CA CA3207106A patent/CA3207106A1/en active Pending
- 2015-06-22 US US14/746,500 patent/US9603864B2/en active Active
- 2015-06-22 AU AU2015280248A patent/AU2015280248B2/en active Active
- 2015-06-22 MX MX2016017383A patent/MX2016017383A/es unknown
- 2015-06-22 WO PCT/US2015/037001 patent/WO2015200219A1/en not_active Ceased
- 2015-06-22 CA CA2952966A patent/CA2952966C/en active Active
- 2015-06-22 CN CN202310927143.6A patent/CN117379452A/zh active Pending
- 2015-06-24 TW TW104120371A patent/TW201613612A/zh unknown
-
2016
- 2016-12-18 IL IL249628A patent/IL249628A0/en unknown
- 2016-12-21 PH PH12016502564A patent/PH12016502564A1/en unknown
-
2017
- 2017-02-02 US US15/423,270 patent/US10307439B2/en active Active
-
2020
- 2020-07-01 JP JP2020114136A patent/JP7080928B2/ja active Active
-
2021
- 2021-07-08 AU AU2021204791A patent/AU2021204791B2/en active Active
-
2022
- 2022-05-25 JP JP2022085181A patent/JP7449978B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201704876B (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| IL273341A (en) | Converted nucleosides, nucleotides and their analogs | |
| IL249628A0 (en) | Nucleosides, modified nucleotides and their analogs | |
| IL249627A0 (en) | Nucleosides, modified nucleotides and their analogs | |
| EP3253773A4 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| IL245014A0 (en) | Nucleosides, modified nucleotides and their analogs | |
| SG11201509585YA (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| IL250836A0 (en) | Nucleotide analogs | |
| EP3013340A4 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| GB2530726B (en) | Distributed single sign-on | |
| IL254409A0 (en) | Nucleotide analogs are mutated at the 5' position | |
| EP3119795A4 (en) | Gemcitabine analogs | |
| SG10201911369PA (en) | Oligonucleotides comprising modified nucleosides | |
| SG11202001495VA (en) | Spirothietane nucleosides | |
| HK1236842A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| HK40034999A (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| TH1501007862A (th) | นิวคลีโอไซด์, นิวคลีโอไทด์และแอนนาลอคที่ถูกแทนที่ของสิ่งเหล่านี้ | |
| HK1227884A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| TH1601002034A (th) | นิวคลีโอไซต์, นิวคลีโอไทด์ ที่ถูกแทนที่ และ สารคล้ายคลึงของสิ่งนั้น | |
| GB201522112D0 (en) | Pram(s) | |
| GB201502660D0 (en) | Hollyman(c) | |
| GB201502892D0 (en) | Multiple retort |